-
Mini-Review: Allicin as a Potential Neuroprotective Compound in Neurological Disorders
-
Evaluation of Umbelliferone Neuroprotective Effects Against Acrylamide-Induced Oxidative Stress, and
-
Effectiveness of Electroconvulsive Therapy in the Remission of Malignant Catatonia Associated With Schizophrenia: A Case Report
-
The Gut-Brain Axis in Alzheimer’s: From Microbiota Genetics to Stigmasterol’s Neuroprotection Mechanism
-
Therapeutic Potential of Naive Hair Follicle Stem Cells in Alzheimer’s Disease: A Comprehensive Evaluation of Neuroprotection and Neurogenesis
-
Notch Signaling Regulates the Neuroprotective Effects of hUCMSCs in a Mouse Model of Cerebral Ischemia
-
Curcumin and an antioxidant formulation protect C57BL/6J mice from MPTP-induced Parkinson’s disease like changes: potential neuroprotection for neurodegeneration
-
Unlocking Neuroprotection: Exercise-Induced Muscle Secretome (Myokines) as a Therapeutic Avenue Against Alzheimer’s Disease Pathogenesis
-
The Global Burden of Schizophrenia: Findings from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study
-
An excitement building in the development of psychological treatments for schizophrenia
-
Comparison of Neurocognitive Effects of Blonanserin, Olanzapine, Aripiprazole, and Risperidone in Drug-Naïve First-Episode Schizophrenia
-
The new German evidence‐ and consensus‐based schizophrenia guideline
-
Temporal recalibration in schizophrenia: a compensatory timing trap?
-
Digital and Biomarker‐Based Monitoring for Schizophrenia‐Treatment Adherence
-
Spermidine in Alzheimer’s Disease: Evidence from Animal Models and Human Studies
-
Identification of Shared Genetic Variants and Haplotypes Associated With Schizophrenia and Depression
-
Pilot Study of Behavioral Activation Treatment for Negative Symptoms in Older Adults With Schizophrenia Spectrum Disorder
-
Towards an integrative and personalized care across the stages of schizophrenia spectrum disorders
-
Interventions in schizophrenia should be transdiagnostic, biologically informed, individualized, and disease modifying
-
The problem of recognition of clinical high‐risk states is hampering the prevention of schizophrenia
-
What does it take to make real‐world changes in schizophrenia care?
-
The Lived Experience of Cognitive Impairment Associated With Schizophrenia: A Conceptual Model
-
Biomarkers in Schizophrenia: Current Approaches and New Developments—A Literature Review
-
Aerobic Exercise for Cognitive and Functional Enhancement in Schizophrenia: Evidence, Mechanisms, and Practical Recommendations
